Cell culture-derived flu vaccine: Present and future

Area of Science:

• Virology and Immunology
• Vaccine Development and Manufacturing

Background:

• Accurately assessing the burden of influenza is complex, making vaccine benefit estimation difficult.
• Quadrivalent influenza vaccines (QIVs) were developed to include both B lineages, enhancing vaccine efficacy.
• Current influenza vaccines are primarily produced using conventional egg-derived methods.

Purpose of the Study:

• To analyze the production challenges associated with egg-derived influenza vaccines.
• To compare egg-derived vaccine production with cell culture-derived influenza vaccines.
• To discuss the future prospects of cell culture-derived QIVs.

Main Methods:

• Comparative analysis of influenza vaccine production methodologies.
• Review of existing literature on egg-based and cell culture-based vaccine manufacturing.
• Discussion of technological advancements and challenges in vaccine production.

Main Results:

• Egg-derived influenza vaccine production faces inherent limitations and challenges.
• Cell culture-derived influenza vaccines offer an alternative production platform.
• Synthetic vaccines represent a novel and emerging approach in influenza vaccine development.

Conclusions:

• Cell culture-derived influenza vaccines present a viable alternative to traditional egg-based methods.
• Further development and adoption of cell culture technology are crucial for future QIV production.
• Advancements in vaccine manufacturing are essential for improving influenza prevention strategies.